Published 14 hours ago • loading... • Updated 14 hours ago

ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm

On April 27, 2026, The Rosen Law Firm filed a securities class action lawsuit against Aldeyra Therapeutics, Inc. on behalf of investors who purchased securities during the Class Period.
According to the lawsuit, defendants failed to disclose that clinical trial results for an Aldeyra drug candidate were inconsistent, rendering purported positive findings unreliable and not meaningful.
Founding partner Laurence Rosen, named a 'Titan of Plaintiffs' Bar,' leads the firm, which has recovered hundreds of millions of dollars for investors and maintains a top-four ranking.
Investors interested in serving as lead plaintiff must move the Court no later than May 29, 2026, though they may also remain absent class members without direct participation.
Those who purchased ALDX securities during the Class Period may contact Phillip Kim, Esq. to join the action without incurring out-of-pocket costs through a contingency fee arrangement.

Insights by Ground AI